Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cancergen.2015.02.008 http://scihub22266oqcxt.onion/10.1016/j.cancergen.2015.02.008 C4494076!4494076!25873528     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Genet 2015 ; 208 (5): 206-14 Nephropedia Template TP {{tp|p=25873528|t=2015. The Roles of Chromatin-Remodelers and Epigenetic Modifiers in Kidney Cancer |pdf=|usr=}}{{25873528}} gab.com Text The Roles of Chromatin-Remodelers and Epigenetic Modifiers in Kidney Cancer JO: Cancer Genet http://www.kidney.de/pget.php?&tw=1&pmid=25873528 #FOAvip Clear cell renal cell carcinoma (ccRCC) is the major subtype of kidney cancer that is characterized by frequent inactivation of von Hippel-Lindau (VHL) gene in 80?90% of the tumors. Recent reports using massive parallel sequencing technologies have discovered more cancer driver genes. PBRM1 was found to be mutated in about 40% of ccRCC tumors, while BAP1 and SETD2 were mutated in about 10?15% of ccRCC tumors each. JARID1C and UTX, two histone H3 demethylases, were also found to harbor mutations in ccRCC, albeit at lower rates. ccRCC tumors display high degree of intra-tumoral heterogeneity, with some mutations present in everyone cancer cells (ubiquitous) while some other subclonal. The VHL mutations were always ubiquitous in the tumors, while PBRM1 mutations were also ubiquitous but to a lesser extent. On the contrary, the mutations in BAP1, SETD2, JARID1C, and UTX were all subclonal, meaning that they were present in a subset of cancer cells in a tumor. The prognosis value of PBRM1 mutations in ccRCC is still controversial, while BAP1 mutations were tightly linked to worse clinical outcome in multiple studies. The molecular functions of these newly identified cancer driver genes were discussed, and they were known reader, writer, or eraser of histone marks on histone H2 and H3 tails that are very close to each other, suggesting that these factors might functionally interact and affect common pathways. The studies on these newly identified tumor suppressors will shed light on ccRCC tumorigenesis and development, and will likely lead to development of novel therapeutic interventions for ccRCC patients. Twit Text FOAVip The Roles of Chromatin-Remodelers and Epigenetic Modifiers in Kidney Cancer ????Cancer Genet http://www.kidney.de/pget.php?&tw=1&pmid=25873528 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25873528 #FOAvip English Wikipedia <ref>{{Cite pmid|25873528}}</ref> The Roles of Chromatin-Remodelers and Epigenetic Modifiers in Kidney Cancer #MMPMID25873528 Liao L; Testa JR; Yang H Cancer Genet 2015[May]; 208 (5): 206-14 PMID25873528show ga Clear cell renal cell carcinoma (ccRCC) is the major subtype of kidney cancer that is characterized by frequent inactivation of von Hippel-Lindau (VHL) gene in 80?90% of the tumors. Recent reports using massive parallel sequencing technologies have discovered more cancer driver genes. PBRM1 was found to be mutated in about 40% of ccRCC tumors, while BAP1 and SETD2 were mutated in about 10?15% of ccRCC tumors each. JARID1C and UTX, two histone H3 demethylases, were also found to harbor mutations in ccRCC, albeit at lower rates. ccRCC tumors display high degree of intra-tumoral heterogeneity, with some mutations present in everyone cancer cells (ubiquitous) while some other subclonal. The VHL mutations were always ubiquitous in the tumors, while PBRM1 mutations were also ubiquitous but to a lesser extent. On the contrary, the mutations in BAP1, SETD2, JARID1C, and UTX were all subclonal, meaning that they were present in a subset of cancer cells in a tumor. The prognosis value of PBRM1 mutations in ccRCC is still controversial, while BAP1 mutations were tightly linked to worse clinical outcome in multiple studies. The molecular functions of these newly identified cancer driver genes were discussed, and they were known reader, writer, or eraser of histone marks on histone H2 and H3 tails that are very close to each other, suggesting that these factors might functionally interact and affect common pathways. The studies on these newly identified tumor suppressors will shed light on ccRCC tumorigenesis and development, and will likely lead to development of novel therapeutic interventions for ccRCC patients. äThe Roles of Chromatin-Remodelers and Epigenetic Modifiers in Kidney C(epmc).pdf DeepDyve Pubget Overpricing